$ATCH
AtlasClear Holdings, Inc.

2024 Q2 Form 10-K Financial Statement

#000141057824000492 Filed on April 16, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $611.9K $2.738M
YoY Change -43.09% -9.47%
Operating Profit -$2.738M
YoY Change -9.47%
Interest Expense $352.5K $3.942M
YoY Change -80.18% -48.49%
% of Operating Profit
Other Income/Expense, Net $636.1K $4.259M
YoY Change -38.75%
Pretax Income $376.7K $1.521M
YoY Change -46.42% -86.87%
Income Tax $3.720K $726.0K
% Of Pretax Income 0.99% 47.73%
Net Earnings $373.0K $795.0K
YoY Change 34.66% -92.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.03 $0.07
COMMON SHARES
Basic Shares Outstanding 12.46M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.42M $619.6K
YoY Change 42674.8% 378.2%
Cash & Equivalents $6.558M $619.6K
Short-Term Investments $54.80M
Other Short-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables $64.84K
Total Short-Term Assets $29.60M $678.4K $678.4K
YoY Change 2341.74% 315.65% 315.65%
LONG-TERM ASSETS
Property, Plant & Equipment $16.08K
YoY Change
Goodwill $7.707M
YoY Change
Intangibles
YoY Change
Long-Term Investments $54.80M $54.80M
YoY Change -73.14% -73.14%
Other Assets $336.0K
YoY Change
Total Long-Term Assets $27.87M $54.80M $54.80M
YoY Change -51.46% -73.14% -73.14%
TOTAL ASSETS
Total Short-Term Assets $29.60M $678.4K $678.4K
Total Long-Term Assets $27.87M $54.80M $54.80M
Total Assets $57.47M $55.48M $55.48M
YoY Change -1.97% -72.83% -72.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.785M $4.785M
YoY Change 11.88% 11.88%
Accrued Expenses $1.528M $1.528M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $480.0K $480.0K
YoY Change 0.0% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $40.68M $12.06M $12.06M
YoY Change 346.32% 114.95% 114.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $307.7K $307.7K
YoY Change 66.67% 66.67%
Total Long-Term Liabilities $307.7K $307.7K
YoY Change 66.67% 66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.68M $12.06M $12.06M
Total Long-Term Liabilities $307.7K $307.7K
Total Liabilities $95.58M $12.37M $12.37M
YoY Change 914.33% 113.41% 113.41%
SHAREHOLDERS EQUITY
Retained Earnings -$148.3M -$11.51M
YoY Change 129.79%
Common Stock $1.246K $503.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$38.11M -$11.51M $43.11M
YoY Change
Total Liabilities & Shareholders Equity $57.47M $55.48M $55.48M
YoY Change -1.97% -72.83% -72.83%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $373.0K $795.0K
YoY Change 34.66% -92.8%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$396.3K -$1.820M
YoY Change -20.14% 67.84%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$480.0K $152.3M
YoY Change -267.26% 43242.27%
Cash From Investing Activities -$480.0K $152.3M
YoY Change -267.26% 43242.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 783.0K -150.0M
YoY Change 206.97% -18872.63%
NET CHANGE
Cash From Operating Activities -396.3K -1.820M
Cash From Investing Activities -480.0K 152.3M
Cash From Financing Activities 783.0K -150.0M
Net Change In Cash -93.26K 490.0K
YoY Change -303.54% 638.17%
FREE CASH FLOW
Cash From Operating Activities -$396.3K -$1.820M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants http://www.atlasclear.com/20231231#FairValueAdjustmentOfNonRedemptionAgreementLiability
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#DerivativeGainLossOnDerivativeNet http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001963088
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5031250
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5031250
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
10081634
CY2022Q4 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
25156250
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
0.5
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41956
CY2023 dei Entity Registrant Name
EntityRegistrantName
AtlasClear Holdings, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
92-2303797
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
4030 Henderson Blvd., Suite 712
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Tampa
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33629
CY2023 dei City Area Code
CityAreaCode
727
CY2023 dei Local Phone Number
LocalPhoneNumber
446-6660
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
ATCH
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
56700000
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12455157
CY2023 dei Auditor Firm
AuditorFirmId
457
CY2023 dei Auditor Name
AuditorName
Haynie & Company
CY2023 dei Auditor Location
AuditorLocation
Salt Lake City, Utah
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
619554
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129560
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33652
CY2023Q4 us-gaap Due From Customer Acceptances
DueFromCustomerAcceptances
58828
CY2023Q4 us-gaap Assets Current
AssetsCurrent
678382
CY2022Q4 us-gaap Assets Current
AssetsCurrent
163212
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
54799478
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
204044469
CY2023Q4 us-gaap Assets
Assets
55477860
CY2022Q4 us-gaap Assets
Assets
204207681
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4784869
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4276705
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount
SharesSubjectToMandatoryRedemptionSettlementTermsAmount
1441653
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
725891
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
536853
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1528101
CY2023Q4 atch Advance From Related Parties
AdvanceFromRelatedParties
3104097
CY2022Q4 atch Advance From Related Parties
AdvanceFromRelatedParties
319166
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
480000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
480000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12064611
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5612724
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
307656
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
184594
CY2023Q4 us-gaap Liabilities
Liabilities
12372267
CY2022Q4 us-gaap Liabilities
Liabilities
5797318
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5050384
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
20125000
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
10.81
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
10.11
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
54618469
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
203420202
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5031250
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5031250
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5050384
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
20125000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
503
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
503
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11513379
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5010342
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11512876
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5009839
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1084259
CY2023 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
1374898
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55477860
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204207681
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2737871
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3024231
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-2737871
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-3024231
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
123062
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6953336
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4566000
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
3090086
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
3087315
CY2023 atch Fair Value Adjustment Of Non Redemption Agreement Liability
FairValueAdjustmentOfNonRedemptionAgreementLiability
439787
CY2023 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
829853
CY2023 us-gaap Interest Income Other
InterestIncomeOther
22195
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4258859
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14606651
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1520988
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11582420
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
726038
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
536853
CY2023 us-gaap Net Income Loss
NetIncomeLoss
794950
CY2022 us-gaap Net Income Loss
NetIncomeLoss
11045567
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-13885204
CY2022 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2170202
CY2022 us-gaap Net Income Loss
NetIncomeLoss
11045567
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5009839
CY2023 us-gaap Excise And Sales Taxes
ExciseAndSalesTaxes
1528101
CY2023 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
120000
CY2023 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-1881440
CY2023 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4008446
CY2023 us-gaap Net Income Loss
NetIncomeLoss
794950
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11512876
CY2023 us-gaap Net Income Loss
NetIncomeLoss
794950
CY2022 us-gaap Net Income Loss
NetIncomeLoss
11045567
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
123062
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6953336
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4566000
CY2023 atch Fair Value Adjustment Of Non Redemption Agreement Liability
FairValueAdjustmentOfNonRedemptionAgreementLiability
439787
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
3090086
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
3087315
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-33652
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-305798
CY2023 us-gaap Increase Decrease In Payables To Broker Dealers
IncreaseDecreaseInPayablesToBrokerDealers
-58828
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
628164
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1634174
CY2023 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
189038
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
536853
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1819835
CY2022 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
351474
CY2023 us-gaap Payments To Invest In Decommissioning Fund
PaymentsToInvestInDecommissioningFund
1850000
CY2023 us-gaap Proceeds From Decommissioning Fund
ProceedsFromDecommissioningFund
152810179
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
152335077
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
351474
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
480000
CY2023 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
70500
CY2023 us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
2855431
CY2022 us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
319166
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
152810179
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-150025248
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
799166
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
489994
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
66381
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129560
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63179
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
619554
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129560
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
537000
CY2023 atch Initial Classification Of Nonredemption Agreement Liability
InitialClassificationOfNonredemptionAgreementLiability
1881440
CY2023 atch Noncash Or Part Noncash Acquisition Cancellation Of Admin Fees
NoncashOrPartNoncashAcquisitionCancellationOfAdminFees
120000
CY2023 atch Excise Taxes Payable Related To Redemptions
ExciseTaxesPayableRelatedToRedemptions
1528101
CY2023 atch Accretion Of Common Stock Subject To Possible Redemption
AccretionOfCommonStockSubjectToPossibleRedemption
4008446
CY2022 atch Accretion Of Common Stock Subject To Possible Redemption
AccretionOfCommonStockSubjectToPossibleRedemption
2170202
CY2021Q1 us-gaap Debt Instrument Term
DebtInstrumentTerm
P185D
CY2021Q1 us-gaap Assets Held In Trust
AssetsHeldInTrust
26250000
CY2023Q4 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
5017526
CY2023 us-gaap Investment Banking Advisory Brokerage And Underwriting Fees And Commissions
InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions
4528125
CY2023 atch Sale Of Stock Other Offering Costs
SaleOfStockOtherOfferingCosts
489401
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
5008178
CY2023 atch Condition For Future Business Combination Use Of Proceeds Percentage
ConditionForFutureBusinessCombinationUseOfProceedsPercentage
0.80
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
175000
CY2023Q3 atch Public Price Per Shares
PublicPricePerShares
0.04
CY2023Q3 atch Public Share Value
PublicShareValue
160000
CY2023Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.53
CY2023Q3 atch Aggregate Shares
AggregateShares
8500897
CY2023Q4 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
4940885
CY2023Q4 us-gaap Partners Capital Account Redemptions
PartnersCapitalAccountRedemptions
53000000.0
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.73
CY2023Q4 us-gaap Cash
Cash
619554
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
619554
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
54799478
CY2023Q4 atch Working Capital Deficit
WorkingCapitalDeficit
11386299
CY2021Q4 atch Working Capital Loans
WorkingCapitalLoans
2000000
CY2023Q4 atch Drawings From Working Capital Loan
DrawingsFromWorkingCapitalLoan
480000
CY2022Q1 atch Additional Working Capital Loan
AdditionalWorkingCapitalLoan
1000000
CY2022Q1 atch Working Capital Loan Net
WorkingCapitalLoanNet
3000000
CY2023Q4 us-gaap Fair Value Option Ineligible Items Aggregate Carrying Amount
FairValueOptionIneligibleItemsAggregateCarryingAmount
3116097
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. The more significant accounting estimates included in these consolidated financial statements is the determination of the fair value of the Private Warrant liabilities, and fair value of the sale of the Founder Shares. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
619554
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021 atch Offering Cost
OfferingCost
9348
CY2023 us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
4008446
CY2023 atch Dissolution Expenses
DissolutionExpenses
100000
CY2021Q4 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
201250000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2170202
CY2022Q4 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
203420202
CY2023 us-gaap Temporary Equity Other Changes
TemporaryEquityOtherChanges
152810179
CY2023 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
4008446
CY2023Q4 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
54618469
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
16215625
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the issuance date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The PIPE derivative was terminated in congruence with the termination of the Merger Agreement with TradeStation. The PIPE derivative met the criteria for derivative liability classification. As such, the PIPE derivative liability was recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the derivative liability were recognized as a non-cash gain or loss on the consolidated statements of operations. The fair value of the derivative liability is discussed in Note 9.</p>
CY2021Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
590625
CY2021Q1 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
718750
CY2021Q1 us-gaap Payments For Rent
PaymentsForRent
10000
CY2022 us-gaap Interest Costs Incurred
InterestCostsIncurred
120000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
0
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
120000
CY2023Q2 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
10000
CY2023Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
120000
CY2023 atch Price Per Warrants1
PricePerWarrants1
1.00
CY2021Q4 atch Working Capital Loans
WorkingCapitalLoans
2000000
CY2022Q1 atch Additional Working Capital Loans
AdditionalWorkingCapitalLoans
1000000
CY2022Q1 atch Working Capital Loan Total Net
WorkingCapitalLoanTotalNet
3000000
CY2022Q1 atch Working Capital Loans
WorkingCapitalLoans
480000
CY2023Q4 atch Principal Balance Amount
PrincipalBalanceAmount
480000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
795000
CY2023Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
3116097
CY2023Q4 atch Marketing Fees Payable To Underwriters As Percentage Of Aggregate Gross Proceeds From Initial Public Offering
MarketingFeesPayableToUnderwritersAsPercentageOfAggregateGrossProceedsFromInitialPublicOffering
0.035
CY2023 atch Revenue Targets Term
RevenueTargetsTerm
P5Y
CY2023Q3 atch Aggregate Shares Of Common Stock
AggregateSharesOfCommonStock
2351800
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1528101
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-239332
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s Common Stock are entitled to one vote for each share.
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s Common Stock are entitled to one vote for each share.
CY2023Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
10081634
CY2022Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
25156250
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5050384
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
20125000
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023 atch Issue Price Per Shares
IssuePricePerShares
9.20
CY2023 atch Proceeds From Other Equity Percentage
ProceedsFromOtherEquityPercentage
0.60
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.50
CY2023 atch Warrant Percentage
WarrantPercentage
1.15
CY2023 atch Issue Price Per Share
IssuePricePerShare
16.50
CY2023 atch Market Value Percentage
MarketValuePercentage
1.65
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6153125
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6153125
CY2023Q4 atch Business Combination Expense
BusinessCombinationExpense
437530
CY2022Q4 atch Business Combination Expense
BusinessCombinationExpense
427319
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
974835
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
745713
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1412365
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1173032
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1412365
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1173032
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
726038
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
536853
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-575221
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-239332
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-575221
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
726038
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
536853
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
239332
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
575221
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.1527
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0051
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0170
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.1261
CY2023 atch Change In Fair Value Of Pipe Derivative Liabilities Percentage
ChangeInFairValueOfPipeDerivativeLiabilitiesPercentage
-0.0607
CY2022 atch Change In Fair Value Of Pipe Derivative Liabilities Percentage
ChangeInFairValueOfPipeDerivativeLiabilitiesPercentage
-0.0828
CY2023 atch Transaction Costs Warrants Percentage
TransactionCostsWarrantsPercentage
0.000
CY2022 atch Transaction Costs Warrants Percentage
TransactionCostsWarrantsPercentage
0.000
CY2023 atch Penalties Interest In Percentage
PenaltiesInterestInPercentage
0.0008
CY2022 atch Penalties Interest In Percentage
PenaltiesInterestInPercentage
0.0007
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.1573
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0497
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.4771
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0464
CY2023Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
54799478
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
204044469
CY2023 atch Withdrawals From Employee Trust Account
WithdrawalsFromEmployeeTrustAccount
1374898
CY2022 atch Withdrawals From Employee Trust Account
WithdrawalsFromEmployeeTrustAccount
351474
CY2023 atch Nonredemption Agreement Liability Shares
NonredemptionAgreementLiabilityShares
235180
CY2023 atch Nonredemption Of Common Stock Shares
NonredemptionOfCommonStockShares
235180
CY2023Q4 us-gaap Share Price
SharePrice
6.20
CY2023Q3 us-gaap Share Price
SharePrice
10.57
CY2023 atch Probability Of Acquisition
ProbabilityOfAcquisition
1.000
CY2023Q3 atch Probability Of Acquisition
ProbabilityOfAcquisition
0.820
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.120
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.199
CY2023 atch Discount For Lack Of Marketability
DiscountForLackOfMarketability
0.0800
CY2023Q3 atch Discount For Lack Of Marketability
DiscountForLackOfMarketability
0.030
CY2023 atch Discount For Expected Forfeiture
DiscountForExpectedForfeiture
0.0511
CY2023Q3 atch Discount For Expected Forfeiture
DiscountForExpectedForfeiture
0.051
CY2022 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0

Files In Submission

Name View Source Status
0001410578-24-000492-index-headers.html Edgar Link pending
0001410578-24-000492-index.html Edgar Link pending
0001410578-24-000492.txt Edgar Link pending
0001410578-24-000492-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20231231.xsd Edgar Link pending
tmb-20231231x10k.htm Edgar Link pending
tmb-20231231xex10d14.htm Edgar Link pending
tmb-20231231xex31d1.htm Edgar Link pending
tmb-20231231xex31d2.htm Edgar Link pending
tmb-20231231xex32d1.htm Edgar Link pending
tmb-20231231xex97d1.htm Edgar Link pending
tmb-20231231_def.xml Edgar Link unprocessable
tmb-20231231_lab.xml Edgar Link unprocessable
tmb-20231231_pre.xml Edgar Link unprocessable
tmb-20231231x10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
tmb-20231231_cal.xml Edgar Link unprocessable